PHAR Pharming Group N.V.
P/E
76.11
Forward P/E
24.39
Price/Sales
2.764
Beta
0.088
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Pharming's third quarter 2026 revenue rose 21% to $117.6M as Joenja sales surged 58%
Pharming Group reported strong financial performance for the third quarter of 2026, with total revenues reaching $117.6 million, a 21% year-over-year increase....
Pharming Group NV Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Pharming Group NV is projected to report Q2 2026 revenue of $82.50 million and an EPS of $0.20, with the current stock price of $1.25 sitting well below the...
Pharming's Cash Cow Is Shrinking — Can Joenja and a Thin Pipeline Justify Investor Patience?
Shares of Pharming Group (PHAR) slid 7.3% to $13.02 on July 10, as investors continue punishing the Dutch rare-disease drugmaker two months after a Q1 2026...
🔴 Pharming Group is trading 7.3% down today on weak Q1 results and falling RUCONEST sales
Pharming Group is trading 7.3% down today at $13.02 as investors continue to react to weak Q1 2026 results and a sharp drop in RUCONEST sales. • The company...